Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Supplements 12(1):7–11. https://doi.org/10.1016/j.kisu.2021.11.003

Article  Google Scholar 

CDC (2023) Chronic Kidney Disease in the United States 2023(22 July)

Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S et al (2015) Diabetic kidney disease. Nat Rev Dis Primers 1(1):15018. https://doi.org/10.1038/nrdp.2015.18

Article  PubMed  PubMed Central  Google Scholar 

Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Cheung M, Jadoul M et al (2020) Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: improving global outcomes consensus conference. Transplantation 104(10):1986–1994. https://doi.org/10.1097/TP.0000000000003360

Article  PubMed  Google Scholar 

Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA et al (2022) A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis 79(2):268–288. https://doi.org/10.1053/j.ajkd.2021.08.003. (e1)

Article  PubMed  Google Scholar 

Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825–830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007

Article  PubMed  Google Scholar 

Matsushita K, Jassal SK, Sang Y, Ballew SH, Grams ME, Surapaneni A et al (2020) Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. EClinicalMedicine 27:100552. https://doi.org/10.1016/j.eclinm.2020.100552

Article  PubMed  PubMed Central  Google Scholar 

Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL et al (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. The Lancet 380(9854):1662–1673. https://doi.org/10.1016/s0140-6736(12)61350-6

Article  Google Scholar 

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM et al (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45(12):3075–3090. https://doi.org/10.2337/dci22-0027

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New Engl J Med 329(20):1456–1462. https://doi.org/10.1056/nejm199311113292004

Article  CAS  PubMed  Google Scholar 

Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y et al (2023) Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110592. https://doi.org/10.1016/j.diabres.2023.110592

Article  CAS  PubMed  Google Scholar 

Naaman SC, Bakris GL (2023) Diabetic nephropathy: update on pillars of therapy slowing progression. Diabetes Care 46(9):1574–1586. https://doi.org/10.2337/dci23-0030

Article  CAS  PubMed  Google Scholar 

Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474–484. https://doi.org/10.1093/eurheartj/ehab777

Article  CAS  PubMed  Google Scholar 

Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018

Article  Google Scholar 

Hsu HT, Chiang YC, Lai YH, Lin LY, Hsieh HF, Chen JL (2021) Effectiveness of multidisciplinary care for chronic kidney disease: a systematic review. Worldviews Evid-Based Nurs 18(1):33–41. https://doi.org/10.1111/wvn.12483

Article  PubMed  Google Scholar 

Nee R, Yuan CM, Narva AS, Yan G, Norris KC (2023) Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant 38(3):532–541. https://doi.org/10.1093/ndt/gfac283

Article  PubMed  Google Scholar 

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845

Article  CAS  PubMed  Google Scholar 

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New Engl J Med 385(24):2252–2263. https://doi.org/10.1056/NEJMoa2110956

Article  CAS  PubMed  Google Scholar 

Frampton JE (2021) Finerenone: first approval. Drugs 81(15):1787–1794. https://doi.org/10.1007/s40265-021-01599-7

Article  CAS  PubMed  Google Scholar 

Kerendia [package insert]. Bayer HealthCare Pharmaceuticals Inc; 2022.

NICE: Finerenone for treating chronic kidney disease in people with type 2 diabetes. https://www.nice.org.uk/guidance/TA877/chapter/1-Recommendations (2023). Accessed 18 September 2023.

Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A (2023) Finerenone: questions and answers—the four fundamental arguments on the new-born promising non-steroidal mineralocorticoid receptor antagonist. J Clin Med 12(12):3992. https://doi.org/10.3390/jcm12123992

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991–2998. https://doi.org/10.2337/dc22-0294

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM et al (2022) Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab 24(1):125–134. https://doi.org/10.1111/dom.14558

Article  CAS  PubMed  Google Scholar 

Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR et al (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117–127. https://doi.org/10.1056/NEJMoa2204233

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med 380(24):2295–2306. https://doi.org/10.1056/nejmoa1811744

Article  CAS  PubMed  Google Scholar 

Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB et al (2023) Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 38(4):894–903. https://doi.org/10.1093/ndt/gfac198

Article  CAS  PubMed  Google Scholar 

De Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K et al (2020) KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98(4):S1–S115. https://doi.org/10.1016/j.kint.2020.06.019

Article  Google Scholar 

Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S et al (2024) Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: a population-based analysis. Eur J Intern Med. https://doi.org/10.1016/j.ejim.2024.03.021

Article  PubMed  Google Scholar 

Bianchi S, Regolisti G (2019) Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrol Dial Transplant 34(Suppl 3):iii51–iii61.